Peptide yy human (3-36)
As of the edition of 20 October 2026, Peptide yy human (3-36) is a protein: went quiet in 2017; acts on NPY2R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2017
- Kind
- Protein
- Registered trials
- 6, 0 stopped early
- Disease areas
- Nutrition and metabolism; Cancer; Hormones; Inherited and neonatal; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route A because of this drug.
Companies on route A for this drug
In the product3 companies are on route A because of Peptide yy human (3-36).
See the 3 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NPY2R | Neuropeptide Y receptor type 2 | P49146 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2006 to now |
| Nastech Pharmaceutical | Lead sponsor of trials | 2007 to now |
| Gila Therapeutics | Lead sponsor of trials | 2017 to now |